文献速递造血干细胞移植与细胞治疗

供受者MDR1基因多态性(G2677TA、C1236T和C3435T)匹配与不匹配对异基因造血干细胞移植后患者结局的影响

The impact of matched and mismatched donor-recipient genotypes for MDR1 polymorphisms (G2677TA, C1236T and C3435T) on the outcomes of patients after allogeneic haematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2024-06-26

本研究纳入100例异基因造血干细胞移植患者及其供者,探讨MDR1基因多态性(G2677TA、C1236T、C3435T)供受者匹配与否与移植后预后的关系。结果显示MDR1 G2677TA匹配组非复发死亡率升高(29.5% vs 6.2%,p=0.002)、总生存期较差(51.7% vs 63.8%,p=0.024)、无病生存期较差(38.6% vs 67%,p=0.005);C1236T和C3435T匹配与不匹配组间OS、DFS、NRM无差异。

要点

  • MDR1 G2677TA供受者匹配与NRM升高、OS和DFS较差相关。
  • MDR1 C1236T和C3435T匹配与否与OS、DFS、NRM无显著差异。
  • 匹配组内男性、HCT-CI≥1、血肌酐>137.2 μmol/L及移植后血小板减少与生存较差相关。

核心结论

  • 接受MDR1 G2677TA匹配的异基因造血干细胞移植患者较不匹配组预后更差。
  • MDR1 G2677TA基因型相容性有望作为选择异基因造血干细胞移植供者的分子工具。

研究设计与样本

  • 纳入100例异基因造血干细胞移植后患者及其供者,分析MDR1 G2677TA、C1236T和C3435T供受者基因型匹配与不匹配与预后的关系。

主要发现

  • MDR1 G2677TA匹配组非复发死亡率为29.5%,不匹配组为6.2%(p=0.002)。
  • MDR1 G2677TA匹配组总生存率为51.7%,不匹配组为63.8%(p=0.024)。
  • MDR1 G2677TA匹配组无病生存率为38.6%,不匹配组为67%(p=0.005)。
  • MDR1 C1236T和C3435T匹配与不匹配组间OS、DFS和NRM均无差异。
  • 亚组分析提示,在MDR1 G2677TA匹配组内,男性、造血干细胞移植特异性合并症指数≥1、血清肌酐>137.2 μmol/L及移植后血小板减少与生存较差相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this study, we investigated whether matched and mismatched multidrug resistance gene (MDR1) genotypes (G2677TA, C1236T and C3435T) were associated with prognosis in patients after allogeneic haematopoietic stem cell transplantation (allo-HSCT). One hundred patients after transplantation and their donors were enrolled. Matched MDR1 G2677TA donor-recipient was associated with an increased risk of non-relapse mortality (NRM) (29.5% vs. 6.2%, p = 0.002), poor overall survival (OS) (51.7% vs. 63.8%, p = 0.024) and disease-free survival (DFS) (38.6% vs. 67%, p = 0.005). There were no differences in OS, DFS or NRM between MDR1 C1236T- and C3435T-matched and -mismatched groups. Subgroup analysis suggested that within the matched MDR1 G2677TA group, male gender, haematopoietic cell transplantation-specific comorbidity index ≥1, serum creatinine >137.2 μmol/L and post-transplantation thrombocytopenia were associated with poor survival. Our results demonstrated that patients receiving matched MDR1 G2677TA allo-HSCT experienced a poorer prognosis compared with the mismatched group. The potential mechanism may involve increased expression of P-glycoprotein, leading to decreased accumulation of antimicrobial agents and ultimately contributing to the progression of inflammation. This identification of MDR1 G2677TA genotype compatibility holds promise as a valuable molecular tool for selecting donors for allo-HSCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Duan Z, Zhang X, Liu Y, et al. The impact of matched and mismatched donor-recipient genotypes for MDR1 polymorphisms (G2677TA, C1236T and C3435T) on the outcomes of patients after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024. PMID: 38924031. doi:10.1111/bjh.19588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。